Mutant bacterial strains of the genus
View Patent ↗The invention relates to mutant strains of the genus Sphingomonas which have a mutation in at least one gene encoding a protein involved in polyhydroxybutyrate (“PHB”) synthesis that allows the mutant strains to produce PHB-deficient sphingans. The invention is also directed to a process for preparing a clarified sphingan solution comprising heating aqueous sphingan solution, in particular PHB-deficient sphingan solution, to a clarification temperature of about 30° C. to about 70° C., and treating the solution with a clarification agent and enzymes. In addition, the invention is directed to a food or industrial product comprising a PHB-deficient and/or clarified sphingan. One particular embodiment of the invention is directed to a clarified, PHB-deficient high-acyl gellan and the processes of making thereof.
1. A process for the preparation of a clarified high acyl gellan solution, comprising the steps of:
(a) heating an aqueous gellan solution to a clarification, temperature of 30 degrees C. to 70 degrees C.;
(b) treating the aqueous gellan solution with at least one chelating agent;
(c) after step (b) treating the chelating agent treated aqueous gellan solution with lysozyme enzyme;
(d) treating the aqueous gellan solution with a caustic agent or an oxidizing agent;
(e) treating the aqueous gellan solution with a protease enzyme; and
(f) recovering the clarified gellan by precipitation with an alcohol,
wherein the resulting clarified gellan upon dissolution at 1% w/w has a light transmittance of greater than 80% measured at a wavelength of 600 to 650 nm.
2. The process according to claim 1 , wherein the aqueous gellan solution is treated with at least one oxidizing agent selected from the group consisting of sodium hypochlorite or other hypochlorite salts, chloride dioxide, hydrogen peroxide, peracetic acid and ozone.
3. The process according to claim 1 , wherein the at least one chelating agent is selected from the group consisting of ethylenediamine tetraacetic acid, phosphoric acid, metaphosphoric acid, carbonic acid, citric acid, tartaric acid, gluconic acid, glutamic acid, pyrophosphoric acid, polyphosphoric acid, metaphosphoric acids, saccharic acid, ethyleneglycol-bis-(beta-aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA), ethylenediamine, 2,3-diaminobutane, 1,2-diaminocyclohexane, triaminotriethylamine, and a salt thereof.
4. The process according to claim 1 , wherein the at least one chelating agent is selected from the group consisting of disodium ethylenediamine tetraacetate, dipotassium ethylenediamine tetraacetate, tetrasodium ethylenediamine tetraacetate, tetrapotassium ethylenediamine tetraacetate, trisodium citrate, tripotassium citrate, sodium hexametaphosphate, potassium hexametaphosphate, sodium polyphosphate, potassium polyphosphate, sodium pyrophosphate, potassium pyrophosphate, monosodium phosphate, monopotassium phosphate, disodium phosphate, dipotassium phosphate, trisodium phosphate, tri potassium phosphate, sodium bicarbonate, sodium carbonate, potassium carbonate, potassium bicarbonate, a cationic ion exchange resin, ethylenediamine dihydrochloride, ethylenediamine diacetate, ethylenediamine lithium salt, ethylenediamine dihydroiodide, and mixtures thereof.
5. The process according to claim 1 , wherein the caustic agent is selected from the group consisting of potassium hydroxide, sodium hydroxide and trisodium phosphate.
6. The process according to claim 1 , wherein the aqueous gellan solution is further treated with a surfactant in step b).
7. The process according to claim 6 , wherein the surfactant is selected from the group consisting of SDS, polyoxyethylenesorbitan monooleate, lecithin, a monoglyceride, a tartaric ester of a monoglyceride, a phosphated monoglyceride, a lactylated monoglyceride, an acetylated monoglyceride, a succinylated monoglyceride, an ethoxylated monoglyceride, a sorbitan ester, a polysorbate, a polyglycerol ester, a sucrose ester, a sodium stearoyl lactylate, and a propylene glycol ester.
8. The process according to claim 1 , wherein the treatment with the lysozyme enzyme is conducted at a pH of 3 to 7.5.
9. The process according to claim 1 , wherein the treatment with the protease enzyme is conducted at a pH of 6.5 to 9.